Evidence map›Paper›PMID 40403210›Full record

ArticleJCO precision oncology2025

Tibor A Zwimpfer, Martin Heidinger, Ricardo Coelho, Nadja Stiegeler, Fabienne D Schwab, Céline Montavon, Ruth S Eller, Nadia Maggi, Julie M Loesch, Marcus Vetter and 4 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in JCO precision oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Tibor A ZwimpferGynecological Cancer Centre, University Hospital Basel and University of Basel, Basel, Switzerland.ORCID 0000-0002-1574-6572
Martin HeidingerGynecological Cancer Centre, University Hospital Basel and University of Basel, Basel, Switzerland.ORCID 0000-0003-2816-1351
Ricardo CoelhoDepartment of Biomedicine, University of Basel, Basel, Switzerland.
Nadja StiegelerDepartment of Gynecology and Obstetrics, Bethesda Hospital Basel, Basel, Switzerland.
Fabienne D SchwabGynecological Cancer Centre, University Hospital Basel and University of Basel, Basel, Switzerland.ORCID 0000-0003-1124-3780
Céline MontavonGynecological Cancer Centre, University Hospital Basel and University of Basel, Basel, Switzerland.ORCID 0000-0002-4186-445X
Ruth S EllerGynecological Cancer Centre, University Hospital Basel and University of Basel, Basel, Switzerland.
Nadia MaggiGynecological Cancer Centre, University Hospital Basel and University of Basel, Basel, Switzerland.
Julie M LoeschBreast Centre, University Hospital Basel and University of Basel, Basel, Switzerland.
Marcus VetterMedical Oncology, Cantonal Hospital Baselland, Medical University Clinic, Liestal, Switzerland.
Matteo LambertiniDepartment of Internal Medicine and Medical Specialties (DIMI), School of Medicine, University of Genova, Genova, Italy.ORCID 0000-0003-1797-5296
Walter P WeberBreast Centre, University Hospital Basel and University of Basel, Basel, Switzerland.ORCID 0000-0003-1667-7844
Christian KurzederGynecological Cancer Centre, University Hospital Basel and University of Basel, Basel, Switzerland.
Viola Heinzelmann-SchwarzGynecological Cancer Centre, University Hospital Basel and University of Basel, Basel, Switzerland.ORCID 0000-0002-4056-3225

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeBreast cancer (BC) is a heterogeneous disease with genetic alterations influencing prognosis and treatment response.

methodsThis retrospective cohort study integrated clinical and genomic data from 4,265 patients with BC from the Molecular Taxonomy of Breast Cancer International Consortium (n = 2,509) and the Memorial Sloan Kettering Cancer Center (n = 1,756). Genetic profiling identified

resultsIn 3,807 patients with available gene alteration status,

conclusion

Indexed as

Breast NeoplasmsPhosphatidylinositol 3-KinasePhosphatidylinositol 3-KinasesProto-Oncogene Proteins c-aktTumor Suppressor Protein p53AdultAgedFemaleHumansMiddle AgedMutationNeoplasm StagingPrognosisRetrospective StudiesSignal TransductionPhosphatidylinositol 3-KinasePhosphatidylinositol 3-KinasesProto-Oncogene Proteins c-aktTP53 protein, humanTumor Suppressor Protein p53

Identifiers

PMID40403210
PMCPMC12122097

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.